Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
Post-Conference Perspectives: Advances in the Management of Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
Medical experts highlight recent findings from the PhALLCON study.
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5